Zacks Research Has Bullish Forecast for CRL Q2 Earnings

Key Points

• Zacks Research has raised its Q2 2026 earnings forecast for Charles River Laboratories to $2.71 per share, up from a previous estimate of $2.70.
• Charles River Laboratories reported $3.12 earnings per share for Q2 2023, significantly exceeding analyst expectations of $2.50.
• The stock has a current consensus rating of "Hold" from analysts, with an average price target of $179.93.

Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) - Zacks Research increased their Q2 2026 earnings per share estimates for shares of Charles River Laboratories International in a report issued on Monday, October 13th. Zacks Research analyst Team now forecasts that the medical research company will post earnings of $2.71 per share for the quarter, up from their previous forecast of $2.70. The consensus estimate for Charles River Laboratories International's current full-year earnings is $9.36 per share. Zacks Research also issued estimates for Charles River Laboratories International's Q3 2026 earnings at $2.62 EPS.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.62. The firm had revenue of $1.03 billion for the quarter, compared to analysts' expectations of $983.76 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The firm's revenue for the quarter was up .6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.80 EPS.

A number of other research analysts have also issued reports on the stock. Wall Street Zen lowered shares of Charles River Laboratories International from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, October 7th. William Blair upgraded shares of Charles River Laboratories International from a "market perform" rating to an "outperform" rating in a research note on Monday, October 6th. JPMorgan Chase & Co. boosted their price target on shares of Charles River Laboratories International from $145.00 to $160.00 and gave the stock a "neutral" rating in a research note on Thursday, August 7th. Evercore ISI upped their target price on shares of Charles River Laboratories International from $190.00 to $200.00 and gave the stock an "outperform" rating in a research report on Friday, October 3rd. Finally, Weiss Ratings restated a "sell (d)" rating on shares of Charles River Laboratories International in a research report on Wednesday, October 8th. Eight analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Charles River Laboratories International presently has a consensus rating of "Hold" and an average target price of $179.93.

Charles River Laboratories International Stock Performance

Shares of CRL stock opened at $170.85 on Tuesday. The stock has a market capitalization of $8.41 billion, a PE ratio of -128.46, a price-to-earnings-growth ratio of 4.47 and a beta of 1.50. Charles River Laboratories International has a 52-week low of $91.86 and a 52-week high of $230.02. The stock's 50-day moving average price is $159.29 and its 200 day moving average price is $147.59. The company has a quick ratio of 1.10, a current ratio of 1.36 and a debt-to-equity ratio of 0.69.

Insider Activity at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 800 shares of the stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $157.60, for a total value of $126,080.00. Following the sale, the executive vice president directly owned 24,116 shares in the company, valued at $3,800,681.60. This represents a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.30% of the stock is owned by corporate insiders.

Institutional Trading of Charles River Laboratories International

Large investors have recently modified their holdings of the business. Goldman Sachs Group Inc. boosted its position in Charles River Laboratories International by 407.0% during the first quarter. Goldman Sachs Group Inc. now owns 997,488 shares of the medical research company's stock worth $150,142,000 after acquiring an additional 800,762 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its position in Charles River Laboratories International by 29.1% during the second quarter. Allspring Global Investments Holdings LLC now owns 2,291,126 shares of the medical research company's stock worth $353,750,000 after acquiring an additional 516,521 shares during the last quarter. Norges Bank acquired a new stake in Charles River Laboratories International during the second quarter worth approximately $76,952,000. Royal Bank of Canada boosted its position in Charles River Laboratories International by 304.7% during the first quarter. Royal Bank of Canada now owns 627,710 shares of the medical research company's stock worth $94,484,000 after acquiring an additional 472,606 shares during the last quarter. Finally, National Bank of Canada FI boosted its position in Charles River Laboratories International by 1,179.5% during the second quarter. National Bank of Canada FI now owns 434,868 shares of the medical research company's stock worth $65,983,000 after acquiring an additional 400,881 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.